Navigation Links
Alcoholism-associated molecular adaptations in brain neurocognitive circuits

After many years of heavy drinking, alcohol produces pathological alterations in the brain. In many alcoholics these changes culminate in massive social deterioration and disorders of memory and learning. Severe cognitive impairments occur in approximately 10% of heavy drinkers. Alcoholic dementia is the second leading course of adult dementia in the Western countries, accounting for 10% of the cases, and still represents an unresolved problem. So far no effective pharmacotherapy for memory problems in alcoholics is available.

Nowadays this problem can be approached by innovative research using molecular and epigenetic analyses, which yield new insight into brain pathophysiology. Molecular dysregulations in endogenous opioids a neurotransmitter system in the brain that is central to reward function and pain control are supposed to play a critical role in the development of alcoholism and associated cognitive impairment.

Professor Georgy Bakalkin, involved in a research team focusing on biochemical mechanisms underlying neuropsychiatric disorders, will highlight the latest findings on this clinical challenge and presents a novel mechanism and understanding of cognitive deficit in human alcoholics. Thereby an emerging concept that proposes a new target for pharmacotherapy will be discussed, which might lead to innovative therapeutic interventions to improve or prevent alcohol-induced cognitive impairment in patients with alcohol dependence, and may be generalized to other learning and memory disorders.


Contact: Sonja Mak
European College of Neuropsychopharmacology

Page: 1

Related medicine news :

1. Schizophrenia linked to dysfunction in molecular brain pathway activated by marijuana
2. New research sheds light on the molecular basis of crib death
3. Solis Womens Health Brings Molecular Breast Imaging to Dallas-Fort Worth Metroplex
4. New Molecular Trigger Described for Hypertension, Diabetes
5. New molecular insight into amboebic dysentery
6. Molecular insight begins Trofex Phase 1 trial for detection of metastatic prostate cancer
7. Molecular insight begins Trofex Ph. 1 trial for detection of metastatic prostate cancer
8. Siemens Showcases Innovative Leadership in Molecular Imaging at SNM 2008
9. Xceed Molecular Licenses Signature from Moffitt Cancer Center and Adds Moffitt to Strategic Collaborator Program
10. DiagnoCures molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings
11. Research reveals molecular fingerprint of cocaine addiction
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast cancers found ... mammography, according to a study published online in the journal Radiology. Researchers said ... may necessitate a change in treatment. , Breast MRI is the most sensitive ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, one of ... its stellar workplace culture with the company’s Cincinnati office being named a finalist ... office was named a finalist in Cincinnati Business Courier’s 13th annual Greater Cincinnati ...
(Date:11/25/2015)... ... , ... On November 10, 2015, Bohrer Brady, LLC filed a class and ... a home health care worker who provided companionship services for the elderly, ill or ... by Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies (CT), Inc. since ...
(Date:11/25/2015)... ... , ... Dental professionals who would like to become more proficient on their ... Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held on December ... of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to announce ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... On November ... of Tri Lite’s personal heating products business. Cozy Products explains what this ... heaters that fit in well with the Cozy Products business model: to sell personal ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: ... and Rugen Therapeutics, a start-up  biotechnology company focused ... CNS disorders and funded by the F-Prime Biomedical ... entered into an exclusive collaboration to support the ... Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... TEL AVIV, Israel , November 25, 2015 /PRNewswire/ ... firms (the "New Investors"), pursuant to which BioLight and ... in BioLight,s IOPtima Ltd. subsidiary ("IOPtima") via a private ... global commercialization of its innovative IOPtimate™ system used in ... a regulatory approval pathway process for the IOPtimate™ system ...
Breaking Medicine Technology: